Dignam named as new RTOG group statistician

James J. Dignam, PhD, has been named the new group statistician for the Radiation Therapy Oncology Group (RTOG) and will lead the efforts of RTOG's Statistics and Data Management Center. 

Dignam is an associate professor of biostatistics in the department of health studies at the University of Chicago and is an investigator at the University of Chicago Cancer Research Center. He has cancer clinical trial research background, having been a statistician for both the National Surgical Adjuvant Breast and Bowel Project and the American College of Surgeons Oncology Group (ACoSOG), in addition to his current work with the University of Chicago.

RTOG is a National Cancer Institute (NCI)-funded national clinical trials group and is administered by the American College of Radiology (ACR).

Around the web

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care. 

After three years of intermittent shortages of nuclear imaging tracer technetium-99m pyrophosphate, there are no signs of the shortage abating.